

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/843,941	04/30/2001	James F. Hemerick	6530.0278	8636
22852	7590 02/09/2005		EXAMINER	
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER			THALER, MICHAEL H	
LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413		ART UNIT	PAPER NUMBER	
		3731		

DATE MAILED: 02/09/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advisory Action	09/843,941	HEMERICK ET AL.				
Advisory Addon	Examiner	Art Unit				
	Michael Thaler	3731				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
THE REPLY FILED 19 January 2005 FAILS TO PLACE Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applica) a timely filed amendment which	ation. A proper reply to a				
PERIOD FOR RE	PLY [check either a) or b)]					
a) The period for reply expiresmonths from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or 2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if imely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFF	R 1.191(d)), to avoid dismissal of					
 The proposed amendment(s) will not be entered be 						
(a) they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) they raise the issue of new matter (see Note below);						
(c) ☐ they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by mate	rially reducing or simplifying the				
(d) they present additional claims without cancell	ng a corresponding number of fi	nally rejected claims.				
NOTE:						
3. Applicant's reply has overcome the following reject	· •					
 Newly proposed or amended claim(s) would canceling the non-allowable claim(s). 	be allowable if submitted in a se	parate, timely filed amendment				
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because: Ple		dered but does NOT place the				
 The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection. 	ause it is not directed SOLELY to	o issues which were newly				
 For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we 						
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: Claim(s) withdrawn from consideration:						
. The drawing correction filed on is a) approved or b) disapproved by the Examiner.						
D. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)						
I0. ☐ Other:						
		mon				
	<u>.</u>	Michael Thaler Primary Examiner Art Unit: 3731				

U.S. Patent and Trademark Office PTOL-303 (Rev. 11-03) Art Unit: 3731

Even assuming arguendo that the stent of Seguin et al. is located proximally with respect to the abutment shoulder described in col. 5, lines 28-34, then the area just distal to the abutment shoulder may be considered to be the claimed stent accommodating area since this area can inherently accommodate a stent therein. Since the Seguin et al. region between rings 21 and 22 has a length which is less than a constrained length of stent 1 to be placed within the outer tubular structure, making this region translucent (in view of Sullivan et al.) would meet the terms of lines 4-7 of claim 1, for example. This is true even if there are other translucent regions distal and proximal to the region between rings 21 and 22. In any event, claim 1 does not even include the stent as part of the claimed combination in view of the phrase "to be placed within the outer tubular structure" in lines 6-7.